Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

diflunisal

A difluorophenyl derivate of salicylic acid and a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory properties. Diflunisal competitively inhibits both cyclooxygenase (COX) -1 and -2, with higher affinity for COX-1, and subsequently blocks the conversion of arachidonic acid to prostaglandin precursors. This leads to an inhibition of the formation of prostaglandins that are involved in pain, inflammation and fever. Diflunisal differs from other salicylates, in that it is not metabolized to salicylic acid, hence it has a longer half-life.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Dolobid
Foreign brand name:Apo-Diflunisal
Flovacil
Novo-Diflunisal
Nu-Diflunisal
Chemical structure:(1,1'-biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-
2',4'-difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search